Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreStandard Treatment Guidelines (STG) and The National Essential Drug List for Tanzania (NEDLIT) (WHO; 1997; 210 pages)
Afficher le documentFOREWORD
Afficher le documentACKNOWLEDGMENTS
Afficher le documentINTRODUCTION
fermer ce répertoireStandard Treatment Guidelines (STG)
ouvrir ce répertoire et afficher son contenu1. GASTROINTESTINAL CONDITIONS
ouvrir ce répertoire et afficher son contenu2. RESPIRATORY DISEASES
ouvrir ce répertoire et afficher son contenu3. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS AND CONTRACEPTION
ouvrir ce répertoire et afficher son contenu4. CARDIOVASCULAR DISEASES
ouvrir ce répertoire et afficher son contenu5. MALARIA
ouvrir ce répertoire et afficher son contenu6. SKIN DISEASES
ouvrir ce répertoire et afficher son contenu7. SEXUALLY TRANSMITTED INFECTIONS / DISEASES (STD)
ouvrir ce répertoire et afficher son contenu8. DENTAL AND ORAL CONDITIONS
ouvrir ce répertoire et afficher son contenu9. GENITO-URINARY DISEASES: KIDNEY CONDITIONS
ouvrir ce répertoire et afficher son contenu10. EAR, NOSE AND THROAT CONDITIONS
ouvrir ce répertoire et afficher son contenu11. EYE CONDITIONS
fermer ce répertoire12. TUBERCULOSIS AND LEPROSY
ouvrir ce répertoire et afficher son contenu12.1 Tuberculosis
fermer ce répertoire12.2 Leprosy
fermer ce répertoire12.2.1 General Information about Leprosy
Afficher le document12.2.1.1 When Leprosy Should be Suspected
Afficher le document12.2.1.2 Diagnosis of Leprosy
ouvrir ce répertoire et afficher son contenu12.2.2 Classification of Leprosy
ouvrir ce répertoire et afficher son contenu12.3 Treatment of Leprosy
Afficher le document12.4 Prevention of Disabilities and rehabilitation
ouvrir ce répertoire et afficher son contenu12.5 Signs and Treatment of Severe Reversal Reaction (RR)
Afficher le document12.6 Responsibilities
Afficher le document12.7 How to Look After Ulcers
Afficher le document12.8 Surveillance of Patients After Release from MDT
Afficher le document12.9 Referral Criteria of Leprosy Patients
ouvrir ce répertoire et afficher son contenu13. MUSCULOSKELETAL CONDITIONS AND JOINT DISEASES
ouvrir ce répertoire et afficher son contenu14. METABOLIC AND ENDOCRINE SYSTEM CONDITIONS
ouvrir ce répertoire et afficher son contenu15. CENTRAL NERVOUS SYSTEM DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu16. OTHER DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu17. VIRAL INFECTIONS
ouvrir ce répertoire et afficher son contenu18. ALLERGIC REACTIONS
ouvrir ce répertoire et afficher son contenu19. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
ouvrir ce répertoire et afficher son contenu20. MALIGNANT DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu21. INJURIES AND TRAUMA
Afficher le document22. FOREIGN BODIES
Afficher le document23. PAIN
Afficher le document24. POISONING
Afficher le document25. NORMAL LABORATORY VALUES
ouvrir ce répertoire et afficher son contenuNATIONAL ESSENTIAL DRUG LIST
Afficher le documentABBREVIATIONS AND SYMBOLS
 
12.2.1 General Information about Leprosy

Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). It mainly affects the skin, the peripheral nerves and the mucous membranes. It is a disease mainly of human beings, which affects people of all races, all ages and both sexes.

Patients harboring many bacilli in their bodies, the multi bacillary patients, are the main sources of infection. If not treated, they spread the disease in the community and infect others through coughing and sneezing (droplet infection). These infectious patients represent only about 25% of the registered leprosy patients in Tanzania. The other 75% of patients with few leprosy bacilli, the paucibacillary patients are less infectious. Skin contact with leprosy patients is no longer considered to be an important means of transmission.

The different manifestations of leprosy are due to differences in the degree of resistance (immunity) of the human body and not due to different kinds of bacilli.

The majority of people (about 85%) have a strong resistance to M. Leprae that even when infected they do not develop the disease. They are immune. About 75% of children who get infected with leprosy bacilli have such a high resistance that they overcome the disease themselves, without treatment, at very early stage. People who have a fairly high but incomplete immunity to leprosy bacilli will develop paucibacillary leprosy.

There are only very few people in the community (5-10%) whose immunity to M. Leprae is naturally very low. When somebody from this group of people is infected by M. Leprae, the bacilli may multiply freely and attain large numbers causing multi-bacillary leprosy.

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires
Abréviations
Anglais  |  Français